Thompson P M, Rosenberger C, Qualls C
Mood Disorders Research Unit, University of New Mexico, Albuquerque, New Mexico 87131, USA.
Neuropsychopharmacology. 1999 Dec;21(6):717-22. doi: 10.1016/S0893-133X(99)00068-8.
Research efforts to identify and understand the pathophysiology of schizophrenia and bipolar illness are limited by the inability to study neuronal tissue of living patients. An alternative to sampling brain tissue from living patients is to measure neuronal proteins found in cerebral spinal fluid. One such candidate protein is synaptosomal-associated protein 25kDa. Our hypothesis is that the level of this protein in cerebral spinal fluid may be a marker of neuronal pathology. Cerebral spinal fluid from headache, schizophrenic, bipolar, and control subjects was used to measure the SNAP-25 level by quantitative dot blotting. Schizophrenic subjects had significantly elevated levels of SNAP-25 as compared to headache and control subjects. However, there was no significant difference between the bipolar group and schizophrenic or control groups. This study reports on a potentially useful clinical marker in schizophrenia, and the presence of elevated cerebral spinal fluid SNAP-25 may indicate alterations in neuronal functioning.
由于无法对活体患者的神经元组织进行研究，识别和理解精神分裂症及双相情感障碍病理生理学的研究工作受到了限制。从活体患者身上采集脑组织样本的替代方法是测量脑脊液中发现的神经元蛋白。一种这样的候选蛋白是25kDa突触体相关蛋白。我们的假设是，这种蛋白在脑脊液中的水平可能是神经元病理学的一个标志物。通过定量斑点印迹法，使用来自头痛患者、精神分裂症患者、双相情感障碍患者及对照受试者的脑脊液来测量SNAP - 25水平。与头痛患者和对照受试者相比时，精神分裂症患者的SNAP - 25水平显著升高。然而，双相情感障碍组与精神分裂症组或对照组之间没有显著差异。本研究报告了一种在精神分裂症中可能有用的临床标志物，脑脊液中SNAP - 25升高可能表明神经元功能发生了改变。
